Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
samedi, octobre 17
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Quest Diagnostics Inc
DGX
NYSE
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$235.00
-4.15
-1.74%
Dern. MÀJ: Oct 16, 4:00 PM
$235.00
-4.15
-1.74%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Dividendes
Comparer
Options
Rapport sur les stocks
Privacy Manager
Résultats:
Résultats Q3 2026 dans dans 5 jours à partir de maintenant le jeu. oct. 22nd, avant l'ouverture du marché
Conférence téléphonique:
Conférence téléphonique prévue dans 5 jours à 8:30 AM
Cliquez pour voir la webdiffusion
Quest Diagnostics Financials
Quest Diagnostics (DGX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winning
Quest Diagnostics (NYSE: DGX) stock jumps after Q2 earnings beat estimates and full-year 2026 guidance gets a boost.
Vandana Singh
Earnings Scheduled For July 23, 2026
Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report
Benzinga Insights
PRO
Quest Diagnostics Raises FY2026 Adj EPS Guidance from $10.63-$10.83 to $11.05-$11.25 vs $10.76 Est; Raises FY2026 Sales Guidance from $11.780B-$11.900B to $11.950B-$12.050B vs $11.851B Est
Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $10.63-$10.83 to $11.05-$11.25 vs $10.76 analyst estimate. Raises FY2026 sales outlook from $11.780 billion-$11.900 billion to $11.950 billion-$12.050
Benzinga Newsdesk
PRO
Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 Est
Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 analyst estimate..
Benzinga Newsdesk
PRO
Quest Diagnostics Q2 Adj. EPS $3.12 Beats $2.83 Estimate, Sales $3.043B Beat $2.973B Estimate
Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $3.12 per share which beat the analyst consensus estimate of $2.83 by 10.25 percent. This is a 19.08 percent increase over earnings of $2.62 per share from the
Benzinga Newsdesk
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Earnings
Quest Diagnostics (DGX) reported strong Q1 earnings, beating expectations and raising guidance. Analysts maintain positive outlook on stock.
Avi Kapoor
